MV06 Culture Medium for Endothelial and Myocardial Cell Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current culture media are inadequate for simultaneously differentiating and expanding endothelial and myocardiac progenitor cells from CD34+ cells, as they either induce apoptosis or promote undesirable cell fusion, and none have successfully mimicked the in vivo differentiation process for clinical applicability.
Innovation Solution
The MV06 culture medium, composed of Iscove's Modified Dubellco's Medium, Fetal calf serum, Horse serum, L-Glutamin, Penicillin/Streptomycin, Hu-R Bone Morphogenic Protein-2, Hu-R Fibroblast Growth Factor-2, and Hu-R Vascular Endothelial Growth Factor, along with an extra-cellular matrix of Fibronectin and Gelatine, supports the in vitro growth and differentiation of both endothelial and myocardiac progenitor cells, maintaining cell viability and promoting differentiation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If Endocult medium is used for CFU-Endothelial Cells culture, then endothelial stem cell quantification is enabled, but purified CD34+ cells undergo apoptosis after 2 days
Solution Approach 1:
The invention changes the cultural parameters by replacing Endocult medium with a new medium composition (M199 or DMEM base medium supplemented with FCS, insulin, transferrin, endothelial all-growth supplement, and heparin) that maintains CD34+ cell viability while enabling endothelial differentiation. This parameter change resolves the contradiction by creating conditions that support both long-term cell survival and accurate endothelial stem cell quantification.
2Productivity
If 5-azacytidine is used for cardiac muscle cell differentiation, then differentiation is induced, but mutagenic effects occur making clinical use dangerous
Solution Approach 1:
The invention eliminates the harmful mutagenic agent 5-azacytidine and replaces it with a safe culture medium approach that naturally induces cardiac muscle cell differentiation. By using a optimized medium composition (M199 or DMEM with specific supplements including FCS, insulin, transferrin, and growth factors) rather than mutagenic chemicals, the invention achieves cardiac differentiation without genotoxicity, making the process suitable for clinical applications.
3Productivity
If co-culture with newborn-rat cardiomyocytes is used for cardiac differentiation, then cardiac muscle cell differentiation is induced, but cell fusion occurs making clinical use inappropriate
Solution Approach 1:
The invention extracts and removes the problematic co-culture system involving newborn-rat cardiomyocytes from the differentiation protocol. Instead of using interspecies co-culture that causes cell fusion, the invention employs a defined culture medium composition that induces cardiac muscle cell differentiation autonomously in human CD34+ cells, eliminating the harmful cell fusion effect while maintaining differentiation efficiency.
4Productivity
If species-specific culture media are used for endothelial or cardiac differentiation, then specific cell type differentiation is achieved, but simultaneous differentiation of both cell types from CD34+ cells is not possible
Solution Approach 1:
The invention creates a universal culture medium composition (M199 or DMEM base medium with FCS, insulin, transferrin, endothelial all-growth supplement, and heparin) that can simultaneously induce both endothelial and cardiac muscle cell differentiation from human CD34+ cells. This multi-functional medium replaces the need for separate species-specific media, enabling dual-lineage differentiation while maintaining cell viability and avoiding harmful effects, thus achieving both specificity and versatility.
Data Source
AI summary
A culture medium named MV06 enabling growth in vitro of both endothelial progenitor and myocardiac progenitor cells, composed of: Iscove's Modified Dubellco's Medium, Fetal calf serum, Horse serum, L-Glutamin (200 mM (100×)) Penicillin (10000 u/mL)/Streptomycin (1000 μg/mL), Hu-R Bone Morphogenetic Protein 2 (BMP-2), Hu-R Fibroblast Growth Factor 2 (FGF2), and Hu-R Vascular Endothelial Growth Factor (VEGF).